FDA Clearance Tracker · P170043-S014
iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular Mi
Last checked: Nov 20, 2026Latest source record: Aug 29, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Aug 29, 2022
Approved
Time to decision
90 days
Received May 31, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P170043-S014
- Device name
- iStent Trabecular Micro-Bypass Stent System, iStent inject Trabecular Micro-Bypass System, iStent inject W Trabecular Mi
- Applicant
- Glaukos Corporation
- Applicant location
- San Clemente, CA
- Received
- May 31, 2022
- Decided
- Aug 29, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P170043
Device type
- Device type
- Intraocular pressure lowering implant (OGO)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for an alternate supplier and modifications to the specifications and incoming receiving testing for the stearalkonium heparin coating raw material.
Source documents
Other decisions for Glaukos Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K220032 · Decided Aug 2, 2022 · 209 days after receipt
Device type: Implant, Eye Valve (KYF) · Ophthalmology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.